Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01391793 · ClinicalTrials.gov registry record · Phase 3

Corticosteroids for Children With Febrile Urinary Tract Infections

A Phase 3 study of Urinary Tract Infection and Acute Urinary Tract Infection, sponsored by Nader Shaikh.

Completed
Registry status
Phase 3
Development phase
546
Enrollment target
6
Study locations

NCT01391793 is a Phase 3 study of Urinary Tract Infection and Acute Urinary Tract Infection that has completed, run by Nader Shaikh. The registered enrollment target is 546 participants, below the 624-participant average among 11 other Urinary Tract Infection trials with a reported enrollment target (12% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01391793, a Phase 3 study of Urinary Tract Infection and Acute Urinary Tract Infection, has completed, sponsored by Nader Shaikh.

COMPLETED
Registry status
Phase 3
Development phase
546 participants
Enrollment target
6
Study locations

Study Summary

In this study the investigators will determine whether corticosteroids given at the time of urinary tract infection help prevent permanent damage to the kidneys.

Interventions

  • DRUG Placebo
  • DRUG Dexamethasone

Study Locations (6)

District of Columbia

  • Children's National Medical Center - Washington D.C.

Ohio

  • Nationwide Children's Hospital in Columbus - Columbus

Pennsylvania

  • Children's Hospital of Pittsburgh - Pittsburgh

Rhode Island

  • Hasbro Children's Hospital - Providence

Utah

  • Primary Children's Hospital - Salt Lake City

Wisconsin

  • American Family Children's Hospital - Madison

Trial Details

FieldValue
Enrollment Target 546 participants
Start Date 2011-09
Est. Completion 2018-03-30
Phase Phase 3

Sponsor

Nader Shaikh

3 total trials

What the Registry Record Tells You About NCT01391793

The ClinicalTrials.gov registry entry for NCT01391793 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 546 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 624-participant average among 11 other Urinary Tract Infection trials with a reported enrollment target (12% lower). The listed sponsor is Nader Shaikh, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Urinary Tract Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01391793 reports 6 study locations spanning 6 distinct geographic areas - top geographies include District of Columbia, Ohio, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01391793 about?

NCT01391793 is a clinical study titled "Corticosteroids for Children With Febrile Urinary Tract Infections". In this study the investigators will determine whether corticosteroids given at the time of urinary tract infection help prevent permanent damage to the kidneys.

What is the current status of trial NCT01391793?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 546 participants. The study started on 2011-09. Estimated completion is 2018-03-30.

What conditions does trial NCT01391793 study?

This clinical trial studies the following conditions: Urinary Tract Infection, Acute Urinary Tract Infection.

What interventions are being tested in trial NCT01391793?

The interventions under investigation include: Placebo (DRUG), Dexamethasone (DRUG).

Who is sponsoring clinical trial NCT01391793?

This trial is sponsored by Nader Shaikh, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01391793 being conducted?

This trial has 6 study locations across District of Columbia, Ohio, Pennsylvania, Rhode Island, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urinary Tract Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.